Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 14/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrimidine SCHEMBL2650905 | 0.88 | GCK (0.53) | GCKKCNH2FFAR2EPHX2CYP1A2 | |
| SCHEMBL2652809 | 0.83 | F11 (0.34) | — | |
| SCHEMBL2651256 | 0.81 | ANO1 (0.33) | GCK | |
| SCHEMBL2664673 | 0.75 | GCK (0.74) | GCKKCNH2FFAR2EPHX2CYP1A2 | |
| SCHEMBL2650845 | 0.75 | GCK (0.70) | GCKKCNH2FFAR2EPHX2CYP1A2 | |
| SCHEMBL2664627 | 0.75 | GCK (0.67) | GCKKCNH2FFAR2EPHX2CYP1A2 | |
| SCHEMBL2645294 | 0.75 | GCK (0.59) | GCKKCNH2FFAR2EPHX2CYP1A2 | |
| SCHEMBL2647924 | 0.74 | GCK (0.71) | GCKKCNH2FFAR2EPHX2CYP1A2 | |
| SCHEMBL2647740 | 0.74 | GCK (0.71) | GCKKCNH2FFAR2EPHX2CYP1A2 | |
| SCHEMBL2647391 | 0.73 | GCK (0.62) | GCKKCNH2FFAR2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1282612-B1 | ALKYNYL PHENYL HETEROAROMATIC GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2004-12-29 | — | — | EP | claimed |
| EP-1282612-A2 | ALKYNYL PHENYL HETEROAROMATIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-12 | — | — | EP | claimed |
| US-6388071-B2 | ANTIDIABETIC AGENTS | HOFFMANN-LA ROCHE INC. | 2002-05-14 | — | — | US | claimed |
| US-20010053851-A1 | Alkynyl phenyl heteroaromatic glucokinase activators | HOFFMAN-LA ROCHE INC. | 2001-12-20 | — | — | US | claimed |
| WO-2001083465-A2 | ALKYNYL PHENYL HETEROAROMATIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-08 | — | — | WO | claimed |
| WO-2006043036-A2 | TREATMENT OF DIABETES | THE UNIVERSITY OF NEWCASTLE (GB) | 2006-04-27 | — | — | WO | disclosed |
| EP-1282612-B1 | ALKYNYL PHENYL HETEROAROMATIC GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2004-12-29 | — | — | EP | disclosed |
| EP-1282612-A2 | ALKYNYL PHENYL HETEROAROMATIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-12 | — | — | EP | disclosed |
| US-6388071-B2 | ANTIDIABETIC AGENTS | HOFFMANN-LA ROCHE INC. | 2002-05-14 | — | — | US | disclosed |
| US-20010053851-A1 | Alkynyl phenyl heteroaromatic glucokinase activators | HOFFMAN-LA ROCHE INC. | 2001-12-20 | — | — | US | disclosed |
| WO-2001083465-A2 | ALKYNYL PHENYL HETEROAROMATIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053851-A1 | Alkynyl phenyl heteroaromatic glucokinase activators | GCK, GCKR, HK2 | GCK 1/4885KCNH2 937/4885FFAR2 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.